Clinical Trials Directory

Trials / Withdrawn

WithdrawnNCT00003486

Antineoplaston Therapy in Treating Patients With Colon Cancer

Phase II Study of Antineoplastons A10 and AS2-1 Capsules in Patients With Adenocarcinoma of the Colon

Status
Withdrawn
Phase
Phase 2
Study type
Interventional
Enrollment
0 (actual)
Sponsor
Burzynski Research Institute · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

RATIONALE: Antineoplastons are naturally occurring substances that may also be made in the laboratory. Antineoplastons may inhibit the growth of cancer cells. PURPOSE: This phase II trial is studying how well antineoplaston therapy works in treating patients with colon cancer.

Detailed description

OBJECTIVES: * Determine the antitumor activity of antineoplastons A10 and AS2-1 in patients with adenocarcinoma of the colon by determining the proportion of patients who experience an objective tumor response. * Evaluate the adverse effects of and tolerance to this regimen in these patients. OUTLINE: This is an open-label study. Patients receive gradually escalating doses of oral antineoplaston A10 and oral antineoplaston AS2-1 6-7 times a day. If the patient has not achieved a partial or complete response after 3-4 months of treatment, the investigator may discontinue treatment. Patients with stable disease may continue to receive treatment until disease progression or unacceptable toxicity is observed. Tumors are measured every 4 months during the first 2 years, then every 6 months during years 3 and 4, and yearly during years 5 and 6. PROJECTED ACCRUAL: A total of 20-40 patients will be accrued for this study.

Conditions

Interventions

TypeNameDescription
DRUGantineoplaston A10
DRUGantineoplaston AS2-1
PROCEDUREalternative product therapy
PROCEDUREbiological therapy
PROCEDUREbiologically based therapies
PROCEDUREcancer prevention intervention
PROCEDUREcomplementary and alternative therapy
PROCEDUREdifferentiation therapy

Timeline

First posted
2003-01-27
Last updated
2013-07-10

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00003486. Inclusion in this directory is not an endorsement.